https://www.selleckchem.com/pr....oducts/atezolizumab.
machine-learning approach for fitting of the models with the highest discriminative ability incorporated several previously validated SIR biomarkers, these failed to improve the discriminative ability of the models to a clinically meaningful degree. While the prognostic and predictive value of such cheap and readily available biomarkers warrants further evaluation in the age of immunotherapy, additional novel biomarkers are still needed to improve risk stratification. While our machine-learning approach for fitting of the models wi
Like
Comment
Share
